Anti-SLC34A2 (Lifastuzumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC
Anti-SLC34A2 (Lifastuzumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (ADC-W-2576)
This ADC product is comprised of an anti-SLC34A2 monoclonal antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA. The duocarmycin SA is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, duocarmycin SA binds to DNA, causes DNA damage.
ADC Target
Name
SLC34A2
Alternative Names
SLC34A2; solute carrier family 34 (type II sodium/phosphate contransporter), member 2; NPTIIb; NAPI-3B; NAPI-IIb; sodium-dependent phosphate transport protein 2B; sodium/phosphate cotransporter 2B; type II sodium-dependent phosphate transporter 3b; solute carrier family 34 (sodium phosphate), member 2;
The protein encoded by this gene is a pH-sensitive sodium-dependent phosphate transporter. Phosphate uptake is increased at lower pH. Defects in this gene are a cause of pulmonary alveolar microlithiasis. Three transcript variants encoding two different isoforms have been found for this gene.
ADC Antibody
Overview
Human Anti-SLC34A2 IgG1-kappa antibody, Lifastuzumab
Generic name
Lifastuzumab
Host animal
Human
ADC Linker
Name
MC-Vc-PAB-DMEA-(PEG2)
Description
Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
ADC payload drug
Name
duocarmycin SA
Description
Duocarmycins SA belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized.